Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Medicine, Hematology, Oncology +12

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis

Tsutomu Akama, Stephen J. Baker, Yongkang Zhang et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 210 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition

Jean‐Baptiste Telliez, Martin E. Dowty, Lu Wang et al. · ACS Chemical Biology · 2016 · 196 citations · Full text

Life Sciences, Immunology, Medicinal Chemistry +17

Discovery of a Potent and Specific <i>M. tuberculosis</i> Leucyl-tRNA Synthetase Inhibitor: (<i>S</i>)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[<i>c</i>][1,2]oxaborol-1(3<i>H</i>)-ol (GSK656)

Xianfeng Li, Vincent Hernandez, Fernando Rock et al. · Journal of Medicinal Chemistry · 2017 · 162 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11